mRNA vaccine platforms: linking infectious disease prevention and cancer immunotherapy
Frontiers in Bioengineering and Biotechnology,
Год журнала:
2025,
Номер
13
Опубликована: Март 12, 2025
The
advent
of
mRNA
vaccines,
accelerated
by
the
global
response
to
COVID-19
pandemic,
marks
a
transformative
shift
in
vaccine
technology.
In
this
article,
we
discuss
development,
current
applications,
and
prospects
vaccines
for
both
prevention
treatment
infectious
diseases
oncology.
By
leveraging
capacity
encode
antigens
within
host
cells
directly,
provide
versatile
scalable
platform
suitable
addressing
broad
spectrum
pathogens
tumor-specific
antigens.
We
highlight
recent
advancements
design,
innovative
delivery
mechanisms,
ongoing
clinical
trials,
with
particular
emphasis
on
their
efficacy
combating
diseases,
such
as
COVID-19,
Zika,
influenza,
well
emerging
potential
cancer
immunotherapy.
also
address
critical
challenges,
including
stability,
optimization
immune
responses,
broader
issue
accessibility.
Finally,
review
strategies
advancing
next-generation
aim
overcoming
limitations
technology
enhancing
preventive
therapeutic
approaches
oncological
diseases.
Язык: Английский
Recent Advances and Prospects in RNA Drug Development
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(22), С. 12284 - 12284
Опубликована: Ноя. 15, 2024
RNA
therapeutics
have
undergone
remarkable
evolution
since
their
inception
in
the
late
1970s,
revolutionizing
medicine
by
offering
new
possibilities
for
treating
previously
intractable
diseases.
The
field
encompasses
various
modalities,
including
antisense
oligonucleotides
(ASOs),
small
interfering
RNAs
(siRNAs),
microRNAs
(miRNAs),
and
messenger
(mRNAs),
each
with
unique
mechanisms
applications.
foundation
was
laid
1978
discovery
that
synthetic
could
inhibit
viral
replication,
followed
pivotal
developments
such
as
interference's
1998.
COVID-19
pandemic
marked
a
crucial
turning
point,
demonstrating
potential
of
mRNA
vaccines
accelerating
interest
RNA-based
approaches.
However,
significant
challenges
remain,
stability
issues,
delivery
to
target
tissues,
off-target
effects,
immunogenicity
concerns.
Recent
advancements
chemical
modifications,
systems,
integration
AI
technologies
are
addressing
these
challenges.
has
seen
notable
successes,
approved
treatments
spinal
muscular
atrophy
hereditary
transthyretin-mediated
amyloidosis.
Looking
ahead,
show
promise
personalized
approaches,
particularly
genetic
disorders
cancer.
continued
this
field,
driven
technological
innovations
deeper
understanding
biology,
suggests
transformative
impact
on
future
medical
treatments.
purpose
review
is
provide
comprehensive
overview
evolution,
current
state,
prospects
therapeutics.
Язык: Английский
Plattformtechnologien in der Impfstoffentwicklung
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 4, 2025
Zusammenfassung
Als
Plattformtechnologien
im
engeren
Sinn
werden
nachfolgend
Ansätze
der
Impfstoffentwicklung
bezeichnet,
bei
denen
Impfstoff
stets
auf
einem
identischen
Grundgerüst
basiert
und
sich
nur
hinsichtlich
des
Antigens
unterscheidet.
Ein
Vorteil
von
besteht
in
raschen
Anpassbarkeit
dieser
Technologien
für
die
Entwicklung
eines
Impfstoffs
gegen
neuartige
Erreger
oder
Varianten.
Bei
derzeit
EU
zugelassenen
Impfstoffen
virale
Vektoren
mRNA
als
Plattformen
verwendet.
dienen
dabei
rekombinante
Adenoviren
(Ad),
das
vesikuläre
Stomatitis-Virus
(VSV)
modifizierte
Vacciniavirus
Ankara
(MVA).
Die
Applikation
mRNA-basierten
erfolgt
Form
Lipidnanopartikeln
(LNPs).
Funktion
LNPs
dem
Schutz
vor
Abbau,
Förderung
Aufnahme
Zellen
einer
Adjuvanswirkung.
Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications
Virology Journal,
Год журнала:
2025,
Номер
22(1)
Опубликована: Март 12, 2025
Messenger
RNA
(mRNA)
vaccines
have
emerged
as
a
transformative
platform
in
modern
vaccinology.
mRNA
vaccine
is
powerful
alternative
to
traditional
due
their
high
potency,
safety,
and
efficacy,
coupled
with
the
ability
for
rapid
clinical
development,
scalability
cost-effectiveness
manufacturing.
Initially
conceptualized
1970s,
first
study
about
effectiveness
of
against
influenza
was
conducted
1993.
Since
then,
development
has
rapidly
gained
significance,
especially
combating
COVID-19
pandemic.
Their
unprecedented
success
during
pandemic,
demonstrated
by
Pfizer-BioNTech
Moderna
vaccines,
highlighted
potential.
This
review
provides
comprehensive
analysis
technology,
detailing
structure
its
mechanism
action
inducing
immunity.
Advancements
nanotechnology,
particularly
lipid
nanoparticles
(LNPs)
delivery
vehicles,
revolutionized
field.
The
manufacturing
processes,
including
upstream
production,
downstream
purification,
formulation
are
also
reviewed.
progress
targeting
viruses
causing
infectious
diseases
discussed,
emphasizing
versatility
therapeutic
Despite
success,
faces
several
challenges,
improved
stability
reduce
dependence
on
cold
chain
logistics
transport,
enhanced
mechanisms
target
specific
tissues
or
cells,
addressing
risk
rare
adverse
events.
High
costs
associated
encapsulation
LNPs
potential
unequal
global
access
further
complicate
widespread
adoption.
As
world
continues
confront
emerging
viral
threats,
overcoming
these
challenges
will
be
essential
fully
harness
vaccines.
It
anticipated
that
play
major
role
defining
shaping
future
health.
Язык: Английский
Animal Trypanosomiasis: Challenges and Prospects for New Vaccination Strategies
Microorganisms,
Год журнала:
2024,
Номер
12(12), С. 2575 - 2575
Опубликована: Дек. 13, 2024
Animal
trypanosomiasis,
such
as
nagana,
surra,
and
dourine,
represent
a
significant
challenge
to
animal
health
economic
development,
especially
in
tropical
subtropical
regions
where
livestock
production
is
an
essential
component
of
country’s
economy.
Despite
advances
the
control
human
diseases
caused
by
several
species
trypanosomes
remain
neglected.
The
lack
funding
for
development
new
treatments
vaccines
contributes
sustaining
severe
impacts
these
have
on
farming
industry,
low-income
rural
areas.
Recent
understanding
immune
processes
involved
during
infection
been
approaches
towards
disease
including
vaccines.
These
must
be
part
integrated
programs,
which
also
include
vector
management
awareness
good
veterinary
practices.
Addressing
challenges
posed
trypanosomiasis
requires
collaborative
continuous
efforts
shared
among
scientists,
governments,
if
progress
made
mitigate
impact
diseases.
In
this
literature
review,
we
discuss
main
research
underway,
prospects
employing
vaccine
platforms,
mRNA
vaccine,
vector-based
CRISPR-attenuated
parasite
vaccine.
Язык: Английский
mRNA vaccines as cancer therapies
Chinese Medical Journal,
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 13, 2024
Abstract
Cancer
remains
a
major
global
health
challenge,
with
conventional
treatments
like
chemotherapy
and
radiotherapy
often
hindered
by
significant
side
effects,
lack
of
specificity,
limited
efficacy
in
advanced
cases.
Among
emerging
therapeutic
strategies,
mRNA
vaccines
have
shown
remarkable
potential
due
to
their
adaptability,
rapid
production,
capability
for
personalized
cancer
treatment.
This
review
provides
an
in-depth
analysis
messenger
RNA
(mRNA)
as
approach
immunotherapy,
focusing
on
molecular
biology,
classification,
mechanisms,
clinical
studies.
Derived
from
reported
literature
data
clinicaltrials.gov,
it
examines
studies
encoding
tumor-specific
antigens
(TSAs),
tumor-associated
(TAAs),
immunomodulators,
chimeric
antigen
receptors
(CARs)
across
various
types.
The
highlights
the
ability
encode
TSAs
TAAs,
enabling
treatments,
classifies
these
into
non-replicating
self-amplifying
It
further
explores
mechanisms
action,
including
presentation
immune
activation,
while
emphasizing
findings
that
demonstrate
therapy.
Despite
promise,
challenges
remain
enhancing
delivery
systems,
improving
immunogenicity,
addressing
tumor
heterogeneity.
Overcoming
obstacles
will
require
investigation
fully
harness
Язык: Английский
Current innovations in mRNA vaccines for targeting multidrug-resistant ESKAPE pathogens
Biotechnology Advances,
Год журнала:
2024,
Номер
unknown, С. 108492 - 108492
Опубликована: Дек. 1, 2024
The
prevalence
of
multidrug-resistant
(MDR)
ESKAPE
pathogens,
including
Enterococcus
faecium,
Staphylococcus
aureus,
Klebsiella
pneumoniae,
Acinetobacter
baumannii,
and
Pseudomonas
aeruginosa,
represents
a
critical
global
public
health
challenge.
In
response,
mRNA
vaccines
offer
an
adaptable
scalable
platform
for
immunotherapy
against
pathogens
by
encoding
specific
antigens
that
stimulate
B-cell-driven
antibody
production
CD8
Язык: Английский